SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly
pandemic: the clinical illness COVID-19. With only one authorized drug
for emergency use in critically ill patients: Remdesivir, there is not
any other approved drug or vaccine yet with proven potential to overcome
this infection. We exposed here many scientific evidences to support our
novel idea that a macrolide, basically Clarithromycin, could be
effective as a single agent for treatment and prophylaxis of COVID-19.
Clarithromycin could change the history of this pandemic. It could
reduce the costs of treatment and the potential adverse effects when
combining more than one drug such as with Hydroxychloroquine.
Clarithromycin treatment and prophylaxis as a single agent could be much
more simple, safe and cheaper as giving Chloroquine or
Hydroxychloroquine alone or in combination with Azithromycin as well as
other therapeutic
options.
Keywords: COVID-19, Macrolides, Clarithromycin, Single Agent,
Therapy, Prophylaxis